Who
Michael Richman
President & CEO
Company insider
Files Form 4 as: President & CEO, NextCure; Director, Palvella Therapeutics; Director, Genvec; Director, Opexa Therapeutics; Director, Cougar Biotechnology.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 28 Jun 2006
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,190 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,190 at $0.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —305,500 at $0.00 | filing |
| 29 Mar 2024filed 2 Apr 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —244,400 at $0.00 | filing |
| 31 Jan 2024filed 1 Feb 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —305,500 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Feb 2023filed 1 Mar 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —309,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Jan 2022filed 2 Feb 2022 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —262,400 at $0.00 | filing |
| 25 Jun 2021filed 29 Jun 2021 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 15 Mar 2021filed 16 Mar 2021 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 23 Jun 2020filed 25 Jun 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Feb 2020filed 3 Mar 2020 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 25 Jan 2020filed 28 Jan 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K5,431 at $2.11 | filing |
| 25 Jan 2020filed 28 Jan 2020 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 25 Oct 2019filed 28 Oct 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K5,165 at $2.12 | filing |
| 25 Jul 2019filed 26 Jul 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K3,789 at $2.89 | filing |
| 25 Apr 2019filed 30 Apr 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K5,640 at $1.94 | filing |
| 25 Jan 2019filed 29 Jan 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $11K6,096 at $1.79 | filing |
| 25 Jan 2019filed 29 Jan 2019 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.